The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobrowolny udział w badaniu i podpisanie zgody
- •Wiek 18 lat lub więcej
- •Dla grupy A: osoby zdrowe
- •Dla grupy B: pacjenci z potwierdzonym rakiem prostaty
✗ Disqualifies
- •Poważne problemy z wątrobą, nerkami lub sercem
- •Znaczna otyłość lub inne warunki uniemożliwiające skanowanie PET/CT
- •Uczulenie na składniki leku badawczego
- •Inne warunki, które badacze uznają za niedopuszczające do udziału
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
The first affiliated hospital of Jinan University
Guangzhou, China
Trial contact
Tingjin Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.